Watch NPHC. Know when insiders buy.
One email the day a filing lands. Free.
NPHC
NUTRA PHARMA CORP
0.00
+0.00 +0.00%
USD · close Sep 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $716KP/E —DIV YIELD —FCF YIELD —REV TTM $161K −49.0%NET INCOME −$5.4MNET DEBT $12.6M52W 0.00 – 0.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $34K | −59.2% | 94.7% | −$435K | −$3.9M | −1168.5% | 0.00 | −$251K | — | — | Aug 19 |
| Q1 2026 · Mar 31 | $27K | −63.2% | 69.6% | −$379K | −$460K | — | 0.00 | −$328K | — | — | May 29 |
| Q4 2025 · Dec 31derived | $29K | −64.7% | -41.3% | −$466K | −$489K | — | 0.00 | −$220K | $0 | −$220K | May 20 |
| Q3 2025 · Sep 30 | $70K | −6.3% | 91.9% | −$356K | −$524K | — | 0.00 | −$251K | $0 | −$251K | Apr 6 |
| Q2 2025 · Jun 30 | $85K | +63.5% | 75.0% | −$291K | $370K | — | 0.00 | −$288K | $0 | −$288K | Aug 19 |
| Q1 2025 · Mar 31 | $74K | +96.1% | 79.9% | −$350K | −$1.4M | — | 0.00 | −$405K | $26K | −$431K | May 29 |
| Q4 2024 · Dec 31derived | $82K | +74.1% | 105.8% | −$179K | −$231K | — | 0.00 | −$178K | — | — | May 20 |
| Q3 2024 · Sep 30 | $75K | +45.3% | 94.3% | −$185K | −$261K | — | 0.00 | $19K | — | — | Apr 6 |
| Q2 2024 · Jun 30 | $52K | — | 106.1% | −$219K | −$367K | — | 0.00 | −$94K | — | — | Mar 25 |
| Q1 2024 · Mar 31 | $38K | — | 93.3% | −$295K | −$427K | — | 0.00 | −$171K | — | — | Mar 11 |
| Q4 2023 · Dec 31derived | $47K | — | 199.3% | −$140K | −$243K | — | 0.00 | −$186K | — | — | Feb 17 |
| Q3 2023 · Sep 30 | $52K | — | 222.8% | −$166K | −$278K | — | 0.00 | −$84K | — | — | Jan 2 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $258K | 76.3% | −$1.5M | −$2M | -794.8% | 0.00 | −$1.2M | $26K | −$1.2M | — | — |
| FY2024 · to Dec 31 | $246K | 100.4% | −$878K | −$1.3M | -522.0% | 0.00 | −$424K | — | — | — | — |
| FY2023 · to Dec 31 | $206K | 192.9% | −$887K | −$1.4M | -677.8% | 0.00 | −$550K | — | — | — | — |
| FY2022 · to Dec 31 | $146K | 170.8% | −$1.9M | $8.2M | 5608.3% | 0.00 | −$762K | $58K | −$820K | — | — |
| FY2021 · to Dec 31 | $98K | 8.7% | −$2M | −$13.1M | -13399.0% | -0.00 | −$1.7M | $39K | −$1.8M | — | — |
| FY2020 · to Dec 31 | $52K | 28.7% | −$925K | −$769K | -1482.1% | 0.00 | −$878K | $6K | −$884K | — | — |
Every number comes from NUTRA PHARMA CORP's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.